| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Macrophages | 17 | 2011 | 643 | 1.530 |
Why?
|
| Cord Blood Stem Cell Transplantation | 9 | 2017 | 91 | 1.350 |
Why?
|
| Leukemia, Myeloid, Acute | 7 | 2018 | 849 | 1.150 |
Why?
|
| Arthritis, Rheumatoid | 11 | 2006 | 189 | 1.140 |
Why?
|
| Transplantation Conditioning | 12 | 2018 | 388 | 1.000 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 6 | 2006 | 212 | 0.840 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 10 | 2018 | 977 | 0.750 |
Why?
|
| Apoptosis | 13 | 2006 | 1752 | 0.740 |
Why?
|
| Neoplasm Proteins | 5 | 2006 | 551 | 0.670 |
Why?
|
| Synovial Membrane | 8 | 2006 | 33 | 0.630 |
Why?
|
| Enbucrilate | 2 | 2011 | 9 | 0.600 |
Why?
|
| Graft vs Host Disease | 8 | 2017 | 379 | 0.590 |
Why?
|
| Monocytes | 7 | 2011 | 219 | 0.590 |
Why?
|
| Embolization, Therapeutic | 3 | 2014 | 320 | 0.550 |
Why?
|
| Mitoxantrone | 1 | 2018 | 65 | 0.530 |
Why?
|
| NF-kappa B | 8 | 2005 | 423 | 0.530 |
Why?
|
| Cytarabine | 1 | 2018 | 218 | 0.510 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2011 | 244 | 0.500 |
Why?
|
| Tumor Necrosis Factor-alpha | 9 | 2006 | 707 | 0.490 |
Why?
|
| Neoplasm, Residual | 2 | 2015 | 206 | 0.480 |
Why?
|
| Cerebral Angiography | 3 | 2014 | 263 | 0.450 |
Why?
|
| Hematologic Neoplasms | 3 | 2016 | 383 | 0.430 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2003 | 682 | 0.430 |
Why?
|
| Pharyngectomy | 1 | 2013 | 8 | 0.410 |
Why?
|
| Lasers, Solid-State | 1 | 2013 | 9 | 0.400 |
Why?
|
| Antineoplastic Agents | 2 | 2018 | 2373 | 0.390 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2013 | 48 | 0.390 |
Why?
|
| Graft Survival | 4 | 2016 | 994 | 0.380 |
Why?
|
| Stem Cell Transplantation | 2 | 2013 | 194 | 0.370 |
Why?
|
| Transplantation, Homologous | 11 | 2018 | 1026 | 0.370 |
Why?
|
| Cell Survival | 6 | 2011 | 1014 | 0.360 |
Why?
|
| Gene Expression Regulation | 7 | 2008 | 2023 | 0.350 |
Why?
|
| Dextrans | 1 | 2011 | 77 | 0.350 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2011 | 67 | 0.340 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2011 | 45 | 0.340 |
Why?
|
| Biliopancreatic Diversion | 1 | 2010 | 3 | 0.330 |
Why?
|
| Induction Chemotherapy | 1 | 2011 | 151 | 0.330 |
Why?
|
| DNA-Binding Proteins | 6 | 2003 | 1255 | 0.320 |
Why?
|
| Intestinal Absorption | 1 | 2010 | 125 | 0.320 |
Why?
|
| Fibroblasts | 6 | 2005 | 767 | 0.320 |
Why?
|
| Aged | 22 | 2018 | 21758 | 0.310 |
Why?
|
| Subtraction Technique | 1 | 2010 | 126 | 0.300 |
Why?
|
| Humans | 51 | 2018 | 98076 | 0.300 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2010 | 177 | 0.300 |
Why?
|
| Gastric Bypass | 1 | 2010 | 119 | 0.300 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2018 | 2658 | 0.290 |
Why?
|
| Middle Aged | 23 | 2018 | 29427 | 0.290 |
Why?
|
| Remission Induction | 3 | 2018 | 754 | 0.290 |
Why?
|
| Brain Infarction | 1 | 2009 | 23 | 0.290 |
Why?
|
| Vertebral Artery Dissection | 1 | 2009 | 24 | 0.290 |
Why?
|
| Carotid Artery, Internal, Dissection | 1 | 2009 | 34 | 0.280 |
Why?
|
| Piperazines | 1 | 2010 | 306 | 0.280 |
Why?
|
| Pyrimidines | 1 | 2010 | 413 | 0.270 |
Why?
|
| Myelodysplastic Syndromes | 3 | 2017 | 385 | 0.270 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2009 | 159 | 0.260 |
Why?
|
| Fetal Blood | 4 | 2017 | 94 | 0.260 |
Why?
|
| Hemodynamics | 1 | 2011 | 747 | 0.260 |
Why?
|
| Haplotypes | 3 | 2016 | 656 | 0.260 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2013 | 1535 | 0.250 |
Why?
|
| Tissue Adhesives | 1 | 2007 | 22 | 0.250 |
Why?
|
| Synovial Fluid | 2 | 2005 | 13 | 0.250 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2014 | 2666 | 0.250 |
Why?
|
| Recurrence | 5 | 2017 | 1254 | 0.240 |
Why?
|
| Adult | 18 | 2018 | 29538 | 0.240 |
Why?
|
| Chimerism | 3 | 2016 | 38 | 0.230 |
Why?
|
| Mitochondria | 5 | 2006 | 650 | 0.230 |
Why?
|
| Survival Analysis | 6 | 2017 | 1527 | 0.230 |
Why?
|
| Treatment Outcome | 11 | 2018 | 9711 | 0.230 |
Why?
|
| Intracellular Membranes | 3 | 2006 | 113 | 0.220 |
Why?
|
| Immunotherapy | 1 | 2011 | 819 | 0.220 |
Why?
|
| Brain Ischemia | 1 | 2009 | 416 | 0.210 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 4 | 2006 | 44 | 0.210 |
Why?
|
| Transcription, Genetic | 3 | 2008 | 1133 | 0.210 |
Why?
|
| Synovitis | 1 | 2004 | 17 | 0.210 |
Why?
|
| Combined Modality Therapy | 4 | 2017 | 1751 | 0.210 |
Why?
|
| Phagocytes | 1 | 2004 | 16 | 0.210 |
Why?
|
| Granulomatosis with Polyangiitis | 1 | 2004 | 14 | 0.200 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2013 | 3605 | 0.200 |
Why?
|
| Vasculitis | 1 | 2004 | 42 | 0.200 |
Why?
|
| Female | 23 | 2018 | 51535 | 0.200 |
Why?
|
| Proto-Oncogene Proteins c-jun | 2 | 2000 | 34 | 0.200 |
Why?
|
| Trans-Activators | 2 | 2003 | 447 | 0.200 |
Why?
|
| Geriatric Assessment | 2 | 2015 | 193 | 0.200 |
Why?
|
| Male | 20 | 2018 | 47075 | 0.190 |
Why?
|
| Caspases | 7 | 2005 | 151 | 0.190 |
Why?
|
| Phosphatidylinositol 3-Kinases | 4 | 2006 | 285 | 0.180 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 4 | 2004 | 403 | 0.160 |
Why?
|
| Membrane Glycoproteins | 4 | 2004 | 446 | 0.160 |
Why?
|
| Retrospective Studies | 7 | 2017 | 10972 | 0.160 |
Why?
|
| Carrier Proteins | 6 | 2004 | 667 | 0.160 |
Why?
|
| STAT3 Transcription Factor | 3 | 2006 | 91 | 0.150 |
Why?
|
| Unrelated Donors | 2 | 2017 | 49 | 0.150 |
Why?
|
| Aged, 80 and over | 6 | 2018 | 7389 | 0.150 |
Why?
|
| Antigens, CD34 | 3 | 2017 | 162 | 0.140 |
Why?
|
| Young Adult | 9 | 2017 | 7507 | 0.140 |
Why?
|
| Nuclear Proteins | 2 | 2000 | 750 | 0.140 |
Why?
|
| Genes, Tumor Suppressor | 1 | 1999 | 156 | 0.140 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2017 | 246 | 0.130 |
Why?
|
| Cells, Cultured | 8 | 2006 | 2855 | 0.130 |
Why?
|
| Comorbidity | 4 | 2018 | 1032 | 0.130 |
Why?
|
| HLA Antigens | 2 | 2016 | 238 | 0.130 |
Why?
|
| Adolescent | 6 | 2017 | 10079 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2003 | 370 | 0.120 |
Why?
|
| Health Services Misuse | 1 | 2016 | 20 | 0.120 |
Why?
|
| Leukemia | 1 | 1999 | 308 | 0.120 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2017 | 150 | 0.120 |
Why?
|
| Tumor Necrosis Factor Receptor-Associated Peptides and Proteins | 2 | 2006 | 6 | 0.120 |
Why?
|
| Azacitidine | 1 | 2017 | 152 | 0.120 |
Why?
|
| Haploidy | 1 | 2016 | 30 | 0.120 |
Why?
|
| Paramyxoviridae | 1 | 2015 | 9 | 0.120 |
Why?
|
| Time Factors | 3 | 2011 | 5567 | 0.120 |
Why?
|
| Enzyme Activation | 5 | 2005 | 679 | 0.120 |
Why?
|
| Lipopolysaccharides | 5 | 2005 | 313 | 0.120 |
Why?
|
| Chromones | 3 | 2006 | 31 | 0.120 |
Why?
|
| Lymphoma | 1 | 2017 | 254 | 0.120 |
Why?
|
| Blood Donors | 1 | 2015 | 24 | 0.110 |
Why?
|
| Morpholines | 3 | 2006 | 67 | 0.110 |
Why?
|
| fas Receptor | 4 | 2004 | 73 | 0.110 |
Why?
|
| Community-Acquired Infections | 1 | 2015 | 65 | 0.110 |
Why?
|
| Sodium Salicylate | 2 | 2006 | 4 | 0.110 |
Why?
|
| Taiwan | 2 | 2011 | 27 | 0.110 |
Why?
|
| Donor Selection | 1 | 2015 | 86 | 0.110 |
Why?
|
| Respiratory Tract Infections | 1 | 2015 | 111 | 0.110 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2015 | 116 | 0.110 |
Why?
|
| Mechanical Thrombolysis | 1 | 2014 | 18 | 0.110 |
Why?
|
| Polyvinyls | 1 | 2014 | 23 | 0.110 |
Why?
|
| Dimethyl Sulfoxide | 1 | 2014 | 45 | 0.100 |
Why?
|
| Cell Differentiation | 4 | 2008 | 1646 | 0.100 |
Why?
|
| Interleukin-6 | 4 | 2004 | 282 | 0.100 |
Why?
|
| Cell Line | 3 | 2011 | 2483 | 0.100 |
Why?
|
| Survival Rate | 2 | 2015 | 2041 | 0.100 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2016 | 330 | 0.100 |
Why?
|
| Glucocorticoids | 1 | 2015 | 370 | 0.100 |
Why?
|
| Adenine Nucleotides | 1 | 2013 | 57 | 0.100 |
Why?
|
| Transplantation, Haploidentical | 3 | 2017 | 29 | 0.100 |
Why?
|
| Arabinonucleosides | 1 | 2013 | 37 | 0.100 |
Why?
|
| Intracranial Arteriovenous Malformations | 1 | 2014 | 147 | 0.100 |
Why?
|
| Transplantation Chimera | 1 | 2013 | 84 | 0.090 |
Why?
|
| Clinical Decision-Making | 1 | 2015 | 305 | 0.090 |
Why?
|
| Apoptosis Regulatory Proteins | 3 | 2004 | 201 | 0.090 |
Why?
|
| Receptors, Cell Surface | 2 | 2004 | 291 | 0.090 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 3 | 2000 | 38 | 0.090 |
Why?
|
| Intensive Care Units | 1 | 2016 | 520 | 0.090 |
Why?
|
| Caspase 8 | 4 | 2005 | 32 | 0.090 |
Why?
|
| Tissue Donors | 2 | 2013 | 581 | 0.090 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2013 | 121 | 0.090 |
Why?
|
| Hematoma, Epidural, Cranial | 1 | 2011 | 3 | 0.090 |
Why?
|
| Extravasation of Diagnostic and Therapeutic Materials | 1 | 2011 | 15 | 0.090 |
Why?
|
| Hematopoiesis | 1 | 2013 | 186 | 0.090 |
Why?
|
| Mice | 7 | 2011 | 12698 | 0.090 |
Why?
|
| Miniaturization | 1 | 2011 | 13 | 0.090 |
Why?
|
| Spectrophotometry | 1 | 2011 | 102 | 0.090 |
Why?
|
| Magnetite Nanoparticles | 1 | 2011 | 27 | 0.090 |
Why?
|
| Flow Cytometry | 2 | 2011 | 720 | 0.090 |
Why?
|
| Neoplasms | 2 | 2018 | 3334 | 0.090 |
Why?
|
| Adult Stem Cells | 1 | 2011 | 31 | 0.090 |
Why?
|
| Scattering, Radiation | 1 | 2011 | 122 | 0.090 |
Why?
|
| Enzyme Inhibitors | 2 | 2006 | 642 | 0.080 |
Why?
|
| Transfection | 4 | 2006 | 883 | 0.080 |
Why?
|
| Incidence | 2 | 2015 | 1779 | 0.080 |
Why?
|
| Reactive Oxygen Species | 2 | 2011 | 525 | 0.080 |
Why?
|
| I-kappa B Proteins | 2 | 2000 | 47 | 0.080 |
Why?
|
| Catheters | 1 | 2011 | 109 | 0.080 |
Why?
|
| Endocytosis | 1 | 2011 | 187 | 0.080 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2004 | 312 | 0.080 |
Why?
|
| Animals | 11 | 2011 | 28894 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2018 | 903 | 0.080 |
Why?
|
| Imatinib Mesylate | 1 | 2010 | 128 | 0.080 |
Why?
|
| Hospitalization | 1 | 2016 | 991 | 0.080 |
Why?
|
| Radiography, Interventional | 1 | 2011 | 157 | 0.080 |
Why?
|
| Transplantation, Autologous | 1 | 2011 | 395 | 0.080 |
Why?
|
| Equipment Design | 1 | 2011 | 425 | 0.080 |
Why?
|
| Intestinal Diseases | 1 | 2010 | 84 | 0.080 |
Why?
|
| Contrast Media | 2 | 2011 | 1011 | 0.080 |
Why?
|
| Illinois | 1 | 2011 | 522 | 0.080 |
Why?
|
| Tomography, Spiral Computed | 1 | 2010 | 75 | 0.080 |
Why?
|
| Benzamides | 1 | 2010 | 260 | 0.080 |
Why?
|
| Brain Injuries | 1 | 2011 | 142 | 0.080 |
Why?
|
| Graft Rejection | 1 | 2016 | 1186 | 0.080 |
Why?
|
| Acute Disease | 1 | 2011 | 860 | 0.070 |
Why?
|
| Membrane Potentials | 3 | 2006 | 406 | 0.070 |
Why?
|
| Fas Ligand Protein | 3 | 2004 | 47 | 0.070 |
Why?
|
| Nanoparticles | 1 | 2011 | 218 | 0.070 |
Why?
|
| Radiation Dosage | 1 | 2010 | 231 | 0.070 |
Why?
|
| Caspase 9 | 3 | 2004 | 47 | 0.070 |
Why?
|
| Adenoviridae | 4 | 2003 | 340 | 0.070 |
Why?
|
| Vertebrobasilar Insufficiency | 1 | 2009 | 25 | 0.070 |
Why?
|
| Vertebral Artery | 1 | 2009 | 33 | 0.070 |
Why?
|
| Neutrophils | 2 | 2016 | 346 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2008 | 889 | 0.070 |
Why?
|
| Carotid Artery, Internal | 1 | 2009 | 74 | 0.070 |
Why?
|
| Pilot Projects | 1 | 2011 | 977 | 0.070 |
Why?
|
| Inflammation | 2 | 2005 | 1120 | 0.070 |
Why?
|
| Prognosis | 2 | 2018 | 4116 | 0.070 |
Why?
|
| T-Lymphocytes | 1 | 2015 | 1327 | 0.070 |
Why?
|
| Interleukin-1 | 2 | 2005 | 72 | 0.070 |
Why?
|
| Arthritis, Experimental | 3 | 2004 | 26 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2011 | 1950 | 0.070 |
Why?
|
| Vascular Surgical Procedures | 1 | 2009 | 166 | 0.060 |
Why?
|
| Promoter Regions, Genetic | 2 | 2001 | 977 | 0.060 |
Why?
|
| Upper Gastrointestinal Tract | 1 | 2007 | 11 | 0.060 |
Why?
|
| Injections, Intra-Arterial | 1 | 2007 | 33 | 0.060 |
Why?
|
| Hemostasis | 1 | 2007 | 25 | 0.060 |
Why?
|
| Caspase 3 | 2 | 2004 | 161 | 0.060 |
Why?
|
| Fatty Acids | 1 | 2008 | 147 | 0.060 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2009 | 194 | 0.060 |
Why?
|
| Steroids | 1 | 2008 | 168 | 0.060 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2006 | 23 | 0.060 |
Why?
|
| Histocompatibility Testing | 2 | 2017 | 145 | 0.060 |
Why?
|
| Cell Adhesion | 1 | 2008 | 419 | 0.060 |
Why?
|
| Base Sequence | 2 | 2001 | 2222 | 0.060 |
Why?
|
| Lipid Metabolism | 1 | 2008 | 221 | 0.060 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 2 | 2004 | 98 | 0.060 |
Why?
|
| Data Interpretation, Statistical | 1 | 2008 | 313 | 0.060 |
Why?
|
| Adenosine Diphosphate | 1 | 2006 | 61 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2004 | 218 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2008 | 700 | 0.060 |
Why?
|
| Necrosis | 1 | 2006 | 212 | 0.060 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 2013 | 0.060 |
Why?
|
| Anticoagulants | 1 | 2009 | 486 | 0.060 |
Why?
|
| Radiography | 1 | 2007 | 764 | 0.050 |
Why?
|
| Adenosine Triphosphate | 1 | 2006 | 319 | 0.050 |
Why?
|
| Transcriptional Activation | 2 | 2003 | 293 | 0.050 |
Why?
|
| RNA, Small Interfering | 1 | 2006 | 564 | 0.050 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2004 | 11 | 0.050 |
Why?
|
| Complement Membrane Attack Complex | 1 | 2004 | 21 | 0.050 |
Why?
|
| Complement System Proteins | 1 | 2004 | 87 | 0.050 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2003 | 85 | 0.050 |
Why?
|
| Genes, bcl-2 | 1 | 2003 | 14 | 0.050 |
Why?
|
| Obesity | 1 | 2010 | 1061 | 0.050 |
Why?
|
| Signal Transduction | 2 | 2006 | 3620 | 0.050 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2003 | 17 | 0.050 |
Why?
|
| Genes, p53 | 1 | 2003 | 108 | 0.050 |
Why?
|
| Adjuvants, Immunologic | 1 | 2004 | 176 | 0.050 |
Why?
|
| Mitochondrial Proteins | 1 | 2004 | 131 | 0.050 |
Why?
|
| In Vitro Techniques | 2 | 2001 | 945 | 0.050 |
Why?
|
| Glycoproteins | 1 | 2004 | 221 | 0.050 |
Why?
|
| Cyclins | 1 | 2003 | 80 | 0.050 |
Why?
|
| Capsid Proteins | 1 | 2002 | 26 | 0.050 |
Why?
|
| Serine | 1 | 2003 | 106 | 0.050 |
Why?
|
| Genes, Regulator | 1 | 2002 | 60 | 0.050 |
Why?
|
| Transgenes | 1 | 2002 | 173 | 0.040 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2002 | 88 | 0.040 |
Why?
|
| Homeostasis | 2 | 2001 | 474 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2008 | 1565 | 0.040 |
Why?
|
| Caspase Inhibitors | 1 | 2001 | 32 | 0.040 |
Why?
|
| Risk Factors | 3 | 2018 | 6232 | 0.040 |
Why?
|
| bcl-Associated Death Protein | 1 | 2001 | 19 | 0.040 |
Why?
|
| Antisense Elements (Genetics) | 1 | 2001 | 9 | 0.040 |
Why?
|
| Serpins | 1 | 2001 | 31 | 0.040 |
Why?
|
| Interleukin-8 | 1 | 2000 | 90 | 0.040 |
Why?
|
| DNA Primers | 1 | 2001 | 530 | 0.040 |
Why?
|
| Phosphorylation | 1 | 2003 | 1145 | 0.040 |
Why?
|
| Transcription Factor RelA | 1 | 2000 | 39 | 0.040 |
Why?
|
| Genetic Vectors | 4 | 2003 | 426 | 0.040 |
Why?
|
| Up-Regulation | 2 | 2001 | 743 | 0.040 |
Why?
|
| Genetic Therapy | 1 | 2002 | 373 | 0.040 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2000 | 38 | 0.040 |
Why?
|
| Prospective Studies | 3 | 2014 | 4823 | 0.040 |
Why?
|
| Viral Proteins | 1 | 2001 | 252 | 0.040 |
Why?
|
| Disease Progression | 2 | 2016 | 1610 | 0.040 |
Why?
|
| Growth Substances | 1 | 1999 | 79 | 0.040 |
Why?
|
| CASP8 and FADD-Like Apoptosis Regulating Protein | 3 | 2004 | 13 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2014 | 1782 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2018 | 102 | 0.030 |
Why?
|
| Sequence Alignment | 1 | 1999 | 353 | 0.030 |
Why?
|
| Lymphocyte Depletion | 1 | 2017 | 103 | 0.030 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2000 | 310 | 0.030 |
Why?
|
| Premedication | 1 | 2017 | 57 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 2000 | 447 | 0.030 |
Why?
|
| Cause of Death | 1 | 2018 | 278 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 1999 | 1028 | 0.030 |
Why?
|
| Immune Tolerance | 1 | 2000 | 386 | 0.030 |
Why?
|
| Child | 1 | 2009 | 7681 | 0.030 |
Why?
|
| Homeodomain Proteins | 1 | 2000 | 566 | 0.030 |
Why?
|
| Protein Binding | 1 | 2000 | 1554 | 0.030 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 2 | 2006 | 7 | 0.030 |
Why?
|
| Histocompatibility | 1 | 2016 | 71 | 0.030 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2015 | 38 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2014 | 3212 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2016 | 215 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2014 | 4025 | 0.030 |
Why?
|
| Complementarity Determining Regions | 1 | 2015 | 26 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 1999 | 2005 | 0.030 |
Why?
|
| Mortality | 1 | 2016 | 159 | 0.030 |
Why?
|
| Terminal Care | 1 | 2016 | 148 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 1999 | 2896 | 0.030 |
Why?
|
| Allografts | 1 | 2015 | 220 | 0.030 |
Why?
|
| Toll-Like Receptor 4 | 2 | 2005 | 95 | 0.030 |
Why?
|
| Prevalence | 1 | 2018 | 1384 | 0.030 |
Why?
|
| Transplant Recipients | 1 | 2015 | 182 | 0.030 |
Why?
|
| Hemostatics | 1 | 2014 | 64 | 0.030 |
Why?
|
| Cysteine Proteinase Inhibitors | 2 | 2006 | 52 | 0.030 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2013 | 33 | 0.020 |
Why?
|
| Pneumococcal Vaccines | 1 | 2013 | 32 | 0.020 |
Why?
|
| Lymphocyte Count | 1 | 2013 | 99 | 0.020 |
Why?
|
| Lymphocyte Subsets | 1 | 2013 | 71 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2017 | 665 | 0.020 |
Why?
|
| Opportunistic Infections | 1 | 2013 | 57 | 0.020 |
Why?
|
| Fas-Associated Death Domain Protein | 2 | 2004 | 7 | 0.020 |
Why?
|
| RNA, Messenger | 3 | 2004 | 2063 | 0.020 |
Why?
|
| Virus Diseases | 1 | 2013 | 83 | 0.020 |
Why?
|
| Rats, Inbred Lew | 2 | 2002 | 219 | 0.020 |
Why?
|
| Transcription Factor AP-1 | 2 | 2003 | 68 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2000 | 1717 | 0.020 |
Why?
|
| Glasgow Coma Scale | 1 | 2011 | 76 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2011 | 141 | 0.020 |
Why?
|
| Injury Severity Score | 1 | 2011 | 165 | 0.020 |
Why?
|
| Age Factors | 1 | 2015 | 1962 | 0.020 |
Why?
|
| NF-KappaB Inhibitor alpha | 2 | 2000 | 38 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2015 | 1013 | 0.020 |
Why?
|
| Trauma Centers | 1 | 2011 | 199 | 0.020 |
Why?
|
| Needs Assessment | 1 | 2011 | 174 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2013 | 446 | 0.020 |
Why?
|
| Decompression, Surgical | 1 | 2011 | 171 | 0.020 |
Why?
|
| Critical Care | 1 | 2011 | 483 | 0.020 |
Why?
|
| Cyclophilins | 1 | 2006 | 8 | 0.010 |
Why?
|
| Mitochondrial ADP, ATP Translocases | 1 | 2006 | 3 | 0.010 |
Why?
|
| Amino Acid Chloromethyl Ketones | 1 | 2006 | 25 | 0.010 |
Why?
|
| bcl-X Protein | 1 | 2006 | 57 | 0.010 |
Why?
|
| Permeability | 1 | 2006 | 145 | 0.010 |
Why?
|
| Rats | 2 | 2002 | 4071 | 0.010 |
Why?
|
| Biological Transport | 1 | 2006 | 401 | 0.010 |
Why?
|
| Cysteine | 1 | 2006 | 149 | 0.010 |
Why?
|
| Cell Death | 1 | 2006 | 257 | 0.010 |
Why?
|
| Annexin A5 | 1 | 2004 | 20 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 2005 | 435 | 0.010 |
Why?
|
| DNA Fragmentation | 1 | 2004 | 65 | 0.010 |
Why?
|
| Receptors, Tumor Necrosis Factor, Member 6b | 1 | 2003 | 1 | 0.010 |
Why?
|
| Adenoviridae Infections | 1 | 2003 | 16 | 0.010 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2003 | 25 | 0.010 |
Why?
|
| Toll-Like Receptors | 1 | 2004 | 106 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2004 | 780 | 0.010 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 1 | 2003 | 13 | 0.010 |
Why?
|
| Growth Inhibitors | 1 | 2003 | 41 | 0.010 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2003 | 11 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2003 | 76 | 0.010 |
Why?
|
| Retinoblastoma Protein | 1 | 2003 | 68 | 0.010 |
Why?
|
| beta-Galactosidase | 1 | 2002 | 65 | 0.010 |
Why?
|
| Hindlimb | 1 | 2002 | 98 | 0.010 |
Why?
|
| Gene Transfer Techniques | 1 | 2002 | 155 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2001 | 122 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2003 | 529 | 0.010 |
Why?
|
| Proton-Motive Force | 1 | 2000 | 1 | 0.010 |
Why?
|
| Replication Protein C | 1 | 2000 | 2 | 0.010 |
Why?
|
| Thiocarbamates | 1 | 2000 | 7 | 0.010 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2000 | 43 | 0.010 |
Why?
|
| Adenoviruses, Human | 1 | 2000 | 41 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2003 | 518 | 0.010 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2000 | 41 | 0.010 |
Why?
|
| Cytomegalovirus | 1 | 2001 | 74 | 0.010 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2000 | 122 | 0.010 |
Why?
|
| Plasmids | 1 | 2001 | 275 | 0.010 |
Why?
|
| Pyrrolidines | 1 | 2000 | 61 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2001 | 310 | 0.010 |
Why?
|
| Recombination, Genetic | 1 | 2002 | 423 | 0.010 |
Why?
|
| Antibodies | 1 | 2001 | 348 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2003 | 2207 | 0.010 |
Why?
|
| Gene Expression | 1 | 2001 | 1320 | 0.010 |
Why?
|
| Skin | 1 | 2000 | 591 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2003 | 2888 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2001 | 2572 | 0.010 |
Why?
|